Core Viewpoint - The gynecological surgical treatment device industry in China is experiencing significant growth, with the market size projected to increase from 50 million yuan in 2017 to 334 million yuan by 2024, reflecting a compound annual growth rate (CAGR) of 31.2% due to rising clinical demand driven by women's health issues and increased awareness [1][8]. Industry Overview - Gynecological surgical treatment devices utilize physical therapy to treat gynecological diseases, with core technologies including infrared thermal radiation, electrical stimulation, and drug ion introduction [3]. - The devices are effective for conditions such as vaginitis, pelvic inflammatory disease, adnexitis, and cervicitis, improving local blood circulation and immune function [3]. Market Dynamics - The main products in the market include microwave therapy devices, radiofrequency therapy devices, infrared therapy devices, low-frequency pulse therapy devices, ozone nebulization therapy devices, and multifunctional integrated therapy devices [4]. - The industry has evolved through three stages: early development (pre-2010), technological upgrades (2010-2020), and intelligent development (2020-present), with increasing integration of AI and big data [5][6]. Policy Support - National policies, such as the "Healthy China 2030" strategy and the "14th Five-Year Plan for Medical Equipment Industry Development," are promoting the enhancement of healthcare services and the modernization of medical equipment, which supports the growth of the gynecological surgical treatment device industry [1][6]. Competitive Landscape - Key players in the industry include companies like Maikangde, Kaili Medical, and Pumen Technology, which focus on cost-effectiveness and localized services [10]. - The market also includes numerous small and medium enterprises, with competition primarily centered around pricing and distribution channels [10]. Future Trends - The industry is moving towards intelligent and precise treatment solutions, with advancements in AI and big data enhancing the operational convenience and treatment accuracy of devices [12][13]. - There is a broad future development space as women's health awareness increases and medical technology advances, with new technologies like remote healthcare emerging [13]. - The application of gynecological surgical treatment devices is expanding into grassroots healthcare settings, supported by government subsidies for medical equipment updates [14].

格隆汇12月18日丨普门科技(688389.SH)在投资者互动平台表示，公司消费者健康线上业务主要依托天 猫、京东等电商平台的旗舰店开展，目前与蚂蚁阿福暂无合作。 ...

Group 1 - The core viewpoint of the article is that Pumen Technology (688389.SH) is primarily conducting its consumer health online business through flagship stores on e-commerce platforms such as Tmall and JD.com, and currently has no collaboration with Ant Group's Aifu [1] Group 2 - The company is leveraging major e-commerce platforms for its online sales strategy [1] - There is no existing partnership with Ant Group's Aifu, indicating a potential area for future collaboration or development [1]

Group 1 - The first extraordinary general meeting of shareholders for Shenzhen Pumen Technology Co., Ltd. was held on December 16, 2025, at the company's headquarters in Shenzhen [2] - All resolutions proposed during the meeting were approved, with no rejected proposals [2] - The meeting was convened by the board of directors and chaired by Chairman Liu Xiancheng, following legal and procedural requirements [2][3] Group 2 - The meeting included the attendance of all 9 current directors and 3 supervisors, along with the board secretary and senior management [3] - Several governance-related proposals were passed, including the cancellation of the supervisory board and amendments to the company's articles of association and related rules [4][5] - A proposal for the company to apply for a comprehensive credit limit from banks for the year 2026 was also approved [5] Group 3 - The company recently received two medical device registration certificates for in vitro diagnostic reagents from the Guangdong Provincial Drug Administration [9] - The registered products are composite quality control products that ensure the safety and effectiveness of the company's electrochemical luminescence detection system [9] - As of the announcement date, the company and its subsidiaries have obtained a total of 105 registration certificates for electrochemical luminescence detection reagents, enhancing its product competitiveness in the immunodiagnostic field [9]

今日焦点 协创数据：拟斥资不超过90亿元采购服务器，主要用于为客户提供云算力服务 协创数据公告称，公司拟向多家供应商采购服务器，并签署相关采购合同，采购合同总金额预计不超过 90亿元，公司购买服务器主要用于为客户提供云算力服务。此次交易不构成重大资产重组，亦不构成关 联交易。公司已通过第四届董事会第九次会议审议通过该议案，尚需提交股东会审议。交易对手方信息 因商业秘密及战略发展考虑不予披露。 华昌达：与上海交大智能制造研究院、上海智能制造功能平台公司签署战略合作框架协议开展具身智能 及人形机器人的联合研发等 华昌达公告称，公司近日与上海交通大学上海智能制造研究院、上海智能制造功能平台有限公司签署 《战略合作框架协议》。三方同意在以下领域开展深度合作：融合具身智能及人形机器人的工业场景数 字化仿真技术与平台；针对机器人技术整体应用解决方案，开展技术转移与联合攻关；开展具身智能及 人形机器人的联合研发，大小脑、技能训练等技术的联合研究；特定用途具身及人形机器人的联合研制 和产业化应用。 航天工程：公司主营业务不涉及商业航天 航天工程发布股票交易异常波动公告称，公司的主营业务是以航天粉煤加压气化技术为核心，专业从事 ...

【重大事项】 中科电气：拟约70亿元投建年产30万吨锂离子电池负极材料一体化项目 中科电气(300035.SZ)公告称，公司与四川泸州（长江）经济开发区管理委员会签订投资协议，拟在四 川泸州（长江）经济开发区投资建设"年产30万吨锂离子电池负极材料一体化项目"，项目计划总投资约 人民币70亿元，分两期建设，一期项目建设年产20万吨锂离子电池负极材料一体化生产基地，计划投资 约47亿元；二期项目建设年产10万吨锂离子电池负极材料一体化生产基地，计划投资约23亿元。项目用 地约1500亩，建设周期为18个月。项目旨在扩大公司锂电负极业务规模，满足不断增长的锂电负极市场 需求，增强综合竞争力，但存在项目用地、审批、建设及市场环境等风险，预计短期内不会对公司业绩 产生重大影响。 今日晚间重要公告抢先看——中科电气拟约70亿元投建年产30万吨锂离子电池负极材料一体化项目；美 格智能发行境外上市股份获得中国证监会备案。 联合精密：拟1.94亿元收购迈特航空51%股权 联合精密(001268.SZ)公告称，公司拟以1.94亿元收购成都迈特航空制造有限公司51%股权。本次交易完 成后，迈特航空将成为公司控股子公司。迈特航空是 ...

证券日报网讯 12月16日晚间，普门科技发布公告称，公司2025年第一次临时股东大会审议通过《关于 取消监事会、修订〈公司章程〉及相关议事规则的议案》《关于修订部分公司治理制度的议案》《关于 2026年度公司向银行申请综合授信额度的议案》。 （文章来源：证券日报） ...

本次取得注册证的产品均为复合质控品，以样本测量程序对质控品进行测定， 将测定结果进行统计分析或与参考值（参考范围）比较，判断结果是否满足要求， 以此确保公司电化学发光检测系统的安全、有效。 证券代码：688389 证券简称：普门科技 公告编号：2025-085 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了2个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： | 产品名称 | 注册 | 注册证 | 注册证 | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | | | 分类 | 编号 | 有效期至 | | | | | | | | | | | 适用于经公司配套校准品校准的全自动 | | 性激素类质 | 类 II | 粤械注准 | 年 2030 | | | 化学发光测定仪及配套试剂组成的公司 | | 控品 ...

北京市中伦（深圳）律师事务所 关于深圳普门科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年十二月 致：深圳普门科技股份有限公司 北京市中伦（深圳）律师事务所（下称"本所"）接受深圳普门科技股份有限公 司（下称"公司"）的委托，指派律师出席公司 2025 年第一次临时股东大会（下称 "本次股东大会"），并根据《中华人民共和国公司法》（下称"《公司法》"）、《上市 公司股东会规则》（下称"《股东会规则》"）等法律、法规和规范性文件及公司现行 章程（下称"《公司章程》"）的有关规定，就本次股东大会的召集和召开程序、召集 人资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意见。 一、本次股东大会的召集和召开程序 为召开本次股东大会，公司董事会于 2025 年 11 月 28 日在《公司章程》规定及 中国证券监督管理委员会指定的信息披露媒体上公告了会议通知。该通知载明了会 议的召开方式、召开时间和召开地点，对会议议题的内容进行了充分披露，说明了 股东有权出席并可委托代理人出席和行使表决权，明确了会议的登记办法、有权出 席会议股东的股权登记日、会议联系人姓名和电话号码，符合《股东会 ...

证券代码：688389 证券简称：普门科技 公告编号：2025-084 深圳普门科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二） 股东大会召开的地点：广东省深圳市龙华区求知东路 8 号普门科技总部 大厦 22 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 97 | | --- | --- | | 普通股股东人数 | 97 | | 2、出席会议的股东所持有的表决权数量 | 241,730,729 | | 普通股股东所持有表决权数量 | 241,730,729 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 56.4151 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.4151 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由董事会召集，由董事 ...